Join IPM at HIV R4P 2016!
Join IPM in Chicago 17-21 Oct. for the 2nd HIV Research for Prevention (R4P) Conference to learn about the latest research advances and how they fit into the HIV prevention landscape.
Find IPM and its partners at the sessions below, where you’ll get updates on the dapivirine ring and other products specifically designed to address women’s HIV prevention and broader sexual and reproductive health needs.
Not attending R4P? Follow us on Twitter at @IPMicrobicides to keep up with news and quotes that catch our eye!
Featured sessions
SA03. The Next Wave in HIV Prevention: Multipurpose Prevention Technologies
Mon. 17 Oct., 08:30-11:30, Michigan Room
Satellite hosted by the Initiative for Multipurpose Prevention Technologies
Speakers include Jonathon Holt, IPM; Martha Brady, Population Council; Mike Chirenje, UZ-UCSF Collaborative Research Programme; Amy Lin, USAID; Kavita Nanda, FHI 360; Joseph Romano, IMPT/NWJ Group; Andrea Thurman, CONRAD; Everlyne Ombati, IMPT/KEMRI
Check out these oral presentations for the latest update on IPM’s MPT ring
Plenary: Which Way is Forward: Emerging Challenges and Opportunities
Wed. 19 Oct., 08:30-10:00, Sheraton Chicago Ballroom IV-VII
Co-chairs: Zeda Rosenberg, Founder and CEO, IPM and Pontiano Kaleebu, Uganda Virus Research Institute (UVRI)
Oral Abstract Session: Pipelines and Platforms for Prevention
Wed. 19 Oct., 10:30-12:00, Chicago Ballroom VIII-X
Co-chairs: Annalene Nel, Chief Medical Officer, IPM and Karl Malcolm, Queens University Belfast (QUB)
Advocacy Corner Session: HIV prevention for women and the dapivirine ring: Next steps for access and advocacy
Wed. 19 Oct., 12:00-13:00, Advocacy Corner
Following the dapivirine ring results released earlier this year, this informal, interactive session will engage attendees in outlining concrete strategies and actions needed to advance the ring and women’s HIV prevention.
Meet the Experts
Wed. 19 Oct., 14:45-15:15, Chicago Ballroom VIII-X
Co-chairs: Zeda Rosenberg, IPM and Pontiano Kaleebu, UVRI
Speakers: Dennis Burton, Scripps Research Institute; Noel Gordon, Human Rights Campaign; Sharon Hillier, University of Pittsburgh
Oral presentations: the dapivirine ring and dapivirine-contraceptive ring
OA03.03. HIV-1 resistance outcomes in seroconverters from the MTN-020/ASPIRE dapivirine vaginal ring study (Microbicide Trials Network [MTN])
Tues. 18 Oct., 11:00-11:15, Chicago Ballroom VI-VII
Oral abstract session: PrEP Problems: Real and Imagined
OA05.03. A validated risk score to predict HIV acquisition in African women: Assessing risk score performance among women who participated in the ASPIRE Trial (MTN)
Tues. 18 Oct., 13:30-13:45, Sheraton Ballroom II-III
Oral abstract session: Risky Business
OA06.06. Assessment of the potential for pharmacodynamic interaction between dapivirine and levonorgestrel when co-administered in an MPT vaginal ring
Tues. 18 Oct., 14:15-14:30, Sheraton Ballroom IV-V
Oral abstract session: Of Mice and (Wo)men: Pharmacokinetics/Pharmacodynamics of Novel Products
Presenter: Jonathon Holt, Director of Preclinical Development, IPM
PD04.01. Pharmacokinetics of dapivirine and levonorgestrel in sheep when administered vaginally in a silicone matrix ring
Tues. 18 Oct., 17:15-17:24, Chicago Ballroom VIII-X
Oral poster session: Prepping for PrEP
Presenter: Jonathon Holt, IPM
Oral Abstract Session: Trust But Verify: Understanding Adherence
Thurs. 20 Oct., 10:30-12:00, Chicago Ballroom VIII-X
IPM’s clinical trial partner MTN will present three abstracts on dapivirine ring adherence data from the ASPIRE study.
Poster presentations: the dapivirine ring and IPM pipeline products
Poster Sessions 01 & 02
Tues. 18 Oct. and Wed. 19 Oct., 17:00-18:30, Level 0, Hall 2
IPM-authored posters
P02: Behavioral and social science research
- P02.12. Vaginal practices in microbicide ring trials in South-Western Uganda
P04: Community engagement in prevention research
- P04.11. Recruiting women at high risk of HIV acquisition into a microbicide trial in South Western Uganda
- P04.25. We cannot do without them: Getting men involved in the vaginal ring study, South Western Uganda
P05: Contraception, pregnancy and HIV prevention
- P05.10. Factors associated with change of contraceptive methods among women at risk of HIV participating in a vaginal microbicide trial in South Western, Uganda
P07: Delivery technologies: novel approaches, formulation and multi-purpose
- P07.12. Impact of butyrate prodrug on extent of LNG binding in platinum-catalysed silicone elastomer vaginal rings
- P07.13. Impact of vaginal ring geometry and drug loading on pharmacokinetics of dapivirine and darunavir in macaques
- P07.16. Novel application of hot melt extrusion for the manufacture of vaginal microbicide films
- P07.24. Intravaginal drug delivery system with dual microbicide delivery
- P07.39. Formulation development of DS003 in ethylene vinyl acetate vaginal rings
- P07.43. Extended release of a combination dapivirine/MK-2048 film for HIV prevention
P08: Discovery and evaluation of biomedical agents
- P08.04. Increased activity of the entry inhibitor DS003, a BMS-806 analogue, through binding to the CD4-induced epitope in HIV-1 gp120
P09: Epidemiology of HIV prevention
- P09.05. High baseline STI prevalence identified during recruitment for three Phase II and a Phase III HIV microbicide study in the Madibeng sub-district
P24: Product acceptability and adherence
- P24.02. Impact of implementing innovative adherence measures during the conduct of a pivotal Phase 3 trial (IPM 027 / The Ring Study)
- P24.19. Optimizing adherence efforts during the conduct of a pivotal Phase 3 dapivirine vaginal ring trial (IPM 027 / The Ring Study)
- P24.21. Objective adherence measurements for the dapivirine vaginal ring
IPM-supported posters
P03: Cellular immunity
- P03.01. 3D printing of microbicide vaginal rings: A proof-of-concept study (QUB)
P05: Contraception, pregnancy and HIV prevention
- P05.06. Uptake of non-hormonal intrauterine contraceptive devices (IUDs) among women participating in MTN-020, a clinical trial for HIV prevention in Africa (MTN)
- P05.11. Early terminations during the MTN-020/ASPIRE study at the CAPRISA eThekwini clinical research site (CRS): A review of screening and termination data (MTN)
P15: Implementation science, including structural interventions, PrEP and VMMC
- P15.10. Cervical abnormalities amongst participants screened for the MTN-020/ASPIRE trial in Hillbrow, Johannesburg (MTN)
P24: Product acceptability and adherence
- P24.03. Are ring worries affecting use? Findings from the MTN-020/ASPIRE Phase III dapivirine ring trial (MTN)
- P24.05. Reasons for participant non-return of vaginal rings in MTN-020/ASPIRE: Potential counselling implications for open-label extension studies (MTN)
- P24.10. Disclosure of vaginal ring use to male partners in an HIV prevention study: Impact on adherence (MTN)
IPM's monthly dapivirine ring has been shown to safely help reduce HIV risk in women. Come to the R4P Advocacy Corner on Wed. 19 Oct., 12:00-13:00, for an interactive session on the next steps for access and advocacy needed to advance the ring!